Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Royal Bank of Canada (TSX: RY )

170.12 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royal Bank of Canada

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
RBC Capital Maintains Outperform Rating for Lexeo Therapeutics: Here's What You Need To Know
Via Benzinga
RBC Just Cut Its Price Target on Lucid Motors (LCID) Stock in Half
LCID stock has fallen by about 25% year-to-date to the $3 level. RBC analyst Tom Narayan believes that's where it should trade. 
Via InvestorPlace
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients. 
Via Benzinga
Why This Analyst Halves Lucid Group's Price Forecast Despite 12%-23% Higher Tech Efficiency Than Tesla
Despite citing Lucid's superior tech efficiency over Tesla, RBC analyst Tom Narayan halves price forecast to $3 from $6, citing concerns over licensing discussions and sedan demand woes. 
Via Benzinga
Carvana Stock Drives Higher On Analyst Upgrade
RBC Capital analyst Brad Erickson said the bear case for the stock has become "increasingly unprovable," and Carvava's recent rally has the potential to continue even higher. The analyst sees any... 
Via Benzinga
Preview: RBC Bearings's Earnings
Via Benzinga
Here's How Much $100 Invested In RBC Bearings 15 Years Ago Would Be Worth Today
Via Benzinga
RBC Capital Maintains Sector Perform Rating for Dana: Here's What You Need To Know
Via Benzinga
RBC Just Doubled Its Price Target on Carvana (CVNA) Stock
Carvana stock is climbing higher on Friday after shares of CVNA got a new price target and rating from RBC Capital analysts. 
Via InvestorPlace
ChargePoint's Shifting Fortunes: Analyst Lowers Forecast Citing Slow EV Market And Emerging Cost Reduction Strategies
ChargePoint Holdings, Inc. (NYSE: CHPT) is downgraded by RBC Capital Markets amid concerns over sluggish EV sales and poor customer sentiment. 
Via Benzinga
What's Going On With GitLab Stock Tuesday?
RBC analyst reiterates GitLab as Outperform with $80 price target. Q4 revenue beat estimates but stock fell on mixed 2025 guidance. Upside potential from new products & growth drivers. 
Via Benzinga
Tesla Investors Need To 'Understand What The Stock Is Ultimately,' Says RBC Analyst: 'It's Not A Car Company'
Tom Narayan, an analyst at RBC Capital Markets, has a unique perspective on Tesla. He believes that the company's core business is not just about cars, but also about autonomy and energy storage. 
Via Benzinga
Newly Listed American Healthcare REIT: Stock Trades At Discount, But Analysts Favor Its Risk-Reward Balance
American Healthcare REIT (AHR) post-IPO success, with Truist's Buy rating projecting 32% return, and RBC's Outperform rating highlighting strong earnings growth. JMP sees potential multiple expansion,... 
Via Benzinga
Lyft And DoorDash Stocks Are Trading Higher Monday - Here's Why
RBC Capital analyst upgraded Lyft & DoorDash stocks, raising price targets. Improved execution, partnerships & growth potential driving confidence. 
Via Benzinga
Lyft And DoorDash Rise On Upgrades. Analyst Says They Should Partner Up.
Lyft stock and DoorDash gained Monday on an upgrade from RBC Capital. Analysts said the two companies could benefit by teaming up. 
Via Investor's Business Daily
RBC Capital Maintains Sector Perform Rating for GMS: Here's What You Need To Know
Via Benzinga
RBC Capital Maintains Outperform Rating for Gaming and Leisure Props: Here's What You Need To Know
Via Benzinga
Shift4 Payments: Analysts Highlight Growth Opportunities Despite Q4 Challenges
RBC Capital analyst maintained Shift4 Payments with Outperform rating and raised price target from $80 to $94. Q1 revenue projected at $279.6M. 
Via Benzinga
Warrior Met Coal's Ballooning Development Costs Prompt Analysts To Rethink Projections
RBC analysts lower price target for Warrior Met Coal to $64 due to higher costs at Blue Creek mine. Capex expected to be $1B in 2024. 
Via Benzinga
Exposures Coal
What's Going On With Booking Holdings Stock After Earnings?
RBC Capital analyst Brad Erickson maintained Booking Holdings with an Outperform and raised the price target from $3550 to $3900, and Wedbush analyst Scott Devitt reiterated Booking Holdings with an... 
Via Benzinga
RBC Capital Maintains Sector Perform Rating for Bausch Health Companies: Here's What You Need To Know
Via Benzinga
Navigating Discover's Merger With Capital One: Analyst Highlights Opportunities And Challenges Ahead
RBC Capital Markets downgrades Discover Financial to Sector Perform with increased price target of $140. Merger with Capital One expected to be accretive and generate $2.7B in synergies. Analyst sees... 
Via Benzinga
Here's How Much You Would Have Made Owning RBC Bearings Stock In The Last 15 Years
Via Benzinga
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset... 
Via Benzinga
RBC Capital Maintains Sector Perform Rating for NMI Holdings: Here's What You Need To Know
Via Benzinga
RBC Illuminates Solar Sector, Launches Coverage For 4 Solar Equipment Leaders
RBC Capital Markets highlighted favorable public policy and declining costs within the solar industry and initiated coverage on several solar equipment suppliers, including First Solar, Enphase Energy,... 
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
RBC Capital Maintains Outperform Rating for Datadog: Here's What You Need To Know
Via Benzinga
Earnings Preview: What To Expect To When Eye Health Company Bausch + Lomb Reports Q4 Performance Later This Month
"Bausch + Lomb's Q4 & FY 2023 results on Feb 21, 2024. Expecting $1.107 billion in sales, $0.17 EPS. RBC Capital predicts $1.159 billion revenue. Insights on Miebo launch and enhanced EBITDA margins... 
Via Benzinga
RBC Capital's Rating Upgrade Propels IGM Biosciences Into Immunology Limelight
IGM Biosciences' strategic shift to immunology with promising bispecific drug, imvotamab. RBC Capital upgraded stock to Outperform, anticipating $21 price target. Data expected in 2H 2024 validates its... 
Via Benzinga
RBC Capital Maintains Sector Perform Rating for Thomson Reuters: Here's What You Need To Know
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.